Patents by Inventor Kenan Christopher Garcia

Kenan Christopher Garcia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200400680
    Abstract: Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
    Type: Application
    Filed: September 3, 2020
    Publication date: December 24, 2020
    Inventors: Michael Edward Birnbaum, Juan Luis Mendoza, Michael Thomas Bethune, David Baltimore, Kenan Christopher Garcia
  • Publication number: 20200400679
    Abstract: Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
    Type: Application
    Filed: September 3, 2020
    Publication date: December 24, 2020
    Inventors: Michael Edward Birnbaum, Juan Luis Mendoza, Michael Thomas Bethune, David Baltimore, Kenan Christopher Garcia
  • Patent number: 10869887
    Abstract: Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: December 22, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenan Christopher Garcia, Jonathan Sockolosky, Lora Picton
  • Publication number: 20200392201
    Abstract: Compositions and methods are provided for peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
    Type: Application
    Filed: August 3, 2020
    Publication date: December 17, 2020
    Inventors: MARVIN GEE, MARK M. DAVIS, ARNOLD HAN, KENAN CHRISTOPHER GARCIA
  • Publication number: 20200385438
    Abstract: Engineered proteins, polynucleotides encoding such proteins, and methods of use thereof are provided, which engineered proteins enhance the sensitivity of a cell to IL-2.
    Type: Application
    Filed: December 5, 2018
    Publication date: December 10, 2020
    Inventors: Kenan Christopher Garcia, Sean Parker, Jonathan Sockolosky, Michael Hollander
  • Patent number: 10844105
    Abstract: De novo designed polypeptides that bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?c heterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: November 24, 2020
    Assignees: University of Washington, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Daniel Adriano Silva Manzano, Shawn Yu, Umut Ulge, David Baker, Kenan Christopher Garcia, Jamie Spangler, Carl Walkey
  • Publication number: 20200347109
    Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??cheterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.
    Type: Application
    Filed: June 23, 2020
    Publication date: November 5, 2020
    Inventors: Daniel Adriano Silva Manzano, Shawn Yu, Umut Ulge, David Baker, Kenan Christopher Garcia, Jamie Spangler, Carl Walkey, Alfredo Quijano Rubio, Brian Weitzner
  • Publication number: 20200339648
    Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??c heterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 29, 2020
    Inventors: Daniel Adriano Silva Manzano, Shawn Yu, Umut Ulge, David Baker, Kenan Christopher Garcia, Jamie Spangler, Carl Walkey, Alfredo Quijano Rubio, Kevin Jude, Brian Weitzner
  • Patent number: 10816554
    Abstract: Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: October 27, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, California Institute of Technology
    Inventors: Michael Edward Birnbaum, Juan Luis Mendoza, Michael Thomas Bethune, David Baltimore, Kenan Christopher Garcia
  • Publication number: 20200317744
    Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??c heterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.
    Type: Application
    Filed: June 23, 2020
    Publication date: October 8, 2020
    Inventors: Daniel Adriano Silva Manzano, Shawn Yu, Umut Ulge, David Baker, Kenan Christopher Garcia, Jamie Spangler, Carl WALKEY
  • Publication number: 20200299349
    Abstract: Provided herein, inter alia, are human interleukin-2 (IL-2) muteins or variants thereof. In particular, provided herein are IL-2 muteins that have a decreased binding capacity for IL-2R?. Such IL-2 muteins are useful, for example, as IL-2 partial agonist in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of autoimmune diseases or conditions). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.
    Type: Application
    Filed: November 20, 2018
    Publication date: September 24, 2020
    Inventors: Kenan Christopher GARCIA, Sonia S. MAJRI, Caleb R. GLASSMAN, Leon Lih-Ren SU
  • Patent number: 10703791
    Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??c heterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: July 7, 2020
    Assignees: University of Washington, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Daniel Adriano Silva Manzano, Shawn Yu, Umut Ulge, David Baker, Kenan Christopher Garcia, Jamie Spangler, Carl Walkey
  • Publication number: 20200199237
    Abstract: Wnt signaling agonist compositions and methods for their use are provided. Wnt signaling agonists of the invention comprise a frizzled binding moiety, which is fused or conjugated to an LRP5 or LRP6 binding moiety and to an R-spondin agonist.
    Type: Application
    Filed: March 5, 2020
    Publication date: June 25, 2020
    Inventors: Kenan Christopher Garcia, Claudia Yvonne Janda
  • Publication number: 20200199238
    Abstract: Wnt signaling agonist compositions and methods for their use are provided. Wnt signaling agonists of the invention comprise a frizzled binding moiety, which is fused or conjugated to an LRP5 or LRP6 binding moiety and to an R-spondin agonist.
    Type: Application
    Filed: March 5, 2020
    Publication date: June 25, 2020
    Inventors: Kenan Christopher Garcia, Claudia Yvonne Janda
  • Publication number: 20200095301
    Abstract: Methods and compositions are provided for enhancing anti-tumor effector immune cells with a targeting construct a human IL-13 superkine. Cytokine or additional co-stimulatory sequences may also be included to enhance the tumoricidal effects of the cells.
    Type: Application
    Filed: December 14, 2017
    Publication date: March 26, 2020
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez, Fahar Merchant
  • Publication number: 20200024338
    Abstract: R-spondin (RSPO) surrogate compositions and methods for their use are provided. RSPO surrogates of the invention comprise (i) a specific binding domain for Ring Finger Protein 43 (RNF43) or Zinc and Ring Finger Protein 3 (ZNRF3) and (ii) a cell targeting domain More specifically, wherein the specific binding domain for RNF43 or ZNRF3 is an antibody fragment, and wherein the cell targeting domain is a cytokine.
    Type: Application
    Filed: January 11, 2018
    Publication date: January 23, 2020
    Inventors: Vincent Christopher Luca, Kenan Christopher Garcia
  • Publication number: 20200010527
    Abstract: Compositions and methods are provided for peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
    Type: Application
    Filed: March 21, 2018
    Publication date: January 9, 2020
    Inventors: Marvin Gee, Mark M. Davis, Arnold Han, Kenan Christopher Garcia
  • Publication number: 20200002398
    Abstract: De novo designed polypeptides that bind to IL-2 receptor ??cheterodimer (IL-2R??c), IL-4 receptor ??cheterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 2, 2020
    Inventors: Daniel Adriano SILVA MANZANO, Shawn YU, Umut ULGE, David BAKER, Kenan Christopher GARCIA, Jamie SPANGLER, Carl WALKEY, Alfredo QUIJANO RUBIO
  • Publication number: 20190248894
    Abstract: This disclosure provides compositions and related methods providing targeted cell-specific inhibition of Notch receptor signaling. The disclosure provides a bi-specific molecule with separate domains that target the intended cell-type and the Notch receptor on that cell-type. The disclosure also provides for nucleic acids, vectors, and cells allowing for the expression of the bi-specific fusion molecules. The disclosure also provides related methods of making and using the bi-specific fusion molecule to inhibit Notch signaling in target cells of interest, including for the treatment of diseases characterized by a dysregulation of Notch signaling.
    Type: Application
    Filed: July 20, 2017
    Publication date: August 15, 2019
    Applicants: Fred Hutchinson Cancer Research Center, The Board of Trustees of The Leland Stanford Junior University
    Inventors: Irwin Bernstein, Vincent Luca, Kenan Christopher Garcia
  • Publication number: 20190248860
    Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.
    Type: Application
    Filed: December 13, 2018
    Publication date: August 15, 2019
    Inventors: Kenan Christopher Garcia, Aron Levin, Aaron Ring